Study urges regulators to adopt cloud platforms to speed drug approvals

A new study led by Nina Cauchon of Amgen and co-authors, published in the Journal of Pharmaceutical Sciences, calls for broader use of cloud-based platforms by regulatory agencies.

The authors argue that moving regulatory processes to the cloud could cut approval timelines dramatically, allowing faster access to medicines.

If adopted, the shift could improve efficiency for both regulators and drug developers, though implementation would require investment in secure digital infrastructure.